FLT3 and acute myeloid leukemia: Several FLT3 protein inhibitors are approved for the treatment of AML (e.g., quizartinib, gilterinib), but loss of clinical efficacy due to the emergence of conferring resistance mutations is common, resulting in high leukemic burden and poor prognosis105.